Drug Profile
Raltegravir - Merck & Co
Alternative Names: Isentress; ISENTRESS HD; L 900612; MK-0518; RALLatest Information Update: 29 Feb 2024
Price :
$50
*
At a glance
- Originator Merck & Co
- Developer Merck & Co; Merck Sharp & Dohme; National Institute of Allergy and Infectious Diseases; The French National Agency for Research on AIDS and Viral Hepatitis; University of Alberta
- Class Antiretrovirals; Naphthyridines; Organic chemicals; Small molecules
- Mechanism of Action HIV integrase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed HIV-1 infections
- Phase II Primary biliary cirrhosis
Most Recent Events
- 01 Jan 2024 University of Alberta in collaboration with Merck Sharp & Dohme completes a phase II trial in Primary biliary cirrhosis (Combination therapy) in Canada (PO) (NCT03954327)
- 02 Jan 2023 Raltegravir is still in phase II trials for Primary biliary cirrhosis in Canada (PO) (NCT03954327)
- 02 Jan 2023 No development reported - Phase-III for HIV-1 infections (Combination therapy, Treatment-naive) in Vietnam and Mozambique (PO)